The prevalence of obesity in patients with type 1 diabetes (T1D) is increasing. Obesity and metabolic syndrome are risk factors which contribute to the development and progression of micro- and macrovascular complications. Several studies have shown the beneficial and durable effect of bariatric surgery in patients with type 2 diabetes, but data in patients with T1D are scarce. We evaluated the impact of bariatric surgery in adult T1D patients enrolled in the T1D Exchange Registry. Clinical characteristics, comorbidities, socioeconomic factors and laboratory data were obtained within 5 years before or after bariatric surgery. A linear mixed model was used to compare glycemic and clinical outcomes before and after surgery controlling for patient characteristics. Overall, data were available for 38 patients of which 34 were female, 31 were white non-Hispanic (2 missing race); age and T1D duration at time of surgery was 43±9 yrs and 22 ± 13 yrs. After bariatric surgery, patients had lower HbA1c (8.7±1.4 before vs. 8.1±1.3% after), BMI (37.3±10.2 vs. 33.0±7.2 kg/m2), and LDL level (88±27 vs. 79±19 mg/dL), but only BMI reached statistical significance (Table). Although limitations include a small number of subjects and lack of information on type of surgery, this is to date the largest sample size. Our results suggest evidence T1D bariatric surgery is associated with improvement in diabetes control, although more research is needed.


F. Vendrame: None. A. Casu: None. R.E. Pratley: Other Relationship; Self; AstraZeneca, Eli Lilly and Company, GlaxoSmithKline plc., Glytec, Janssen Scientific Affairs, LLC., Lexicon Pharmaceuticals, Inc., Ligand Pharmaceuticals Incorporated, Merck & Co., Inc., Novo Nordisk Inc., Sanofi. P. Calhoun: Stock/Shareholder; Self; Dexcom, Inc.


The Leona M. and Harry B. Helmsley Charitable Trust (G-2016PG-T1D053)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at